Sun Pharma latest to sell COVID-19 drug favipiravir in India – ZAWYA

Sun Pharma latest to sell COVID-19 drug favipiravir in India – ZAWYA

Sun Pharma latest to sell COVID-19 drug favipiravir in India Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India    A guard walks inside the office of Sun Pharmaceutical Industries Ltd in Mumbai, India, November 13, 2018.BENGALURU - India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation.Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday.Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available. Stocks will be available from this week.Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday.BENGALURU - India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of